🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Poland
Clinical trial register · European Union · CTIS

Clinical Trials in Poland

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 19 Sep 2026, 04:26 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
14 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase IV
A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by hypercortisolaemia due to Cushing’s Syndrome
2025-524649-28-00Cushing's syndrome
Recordati AG
Hormonal diseases
Germany, Bulgaria, France, Romania, Italy, Poland, Spain
08/09/2026
Phase IV
Effectiveness of Trazodone on Emotional Blunting in Patients with Major Depressive: a Phase IV, Open-label, clinical study
2025-523267-38-00Major depressive disorder (MDD)
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Mental Disorders
Bulgaria, Poland, Hungary
29/07/2026
Phase IV
Phase IV study evaluating the efficacy and safety of the venetoclax + rituximab (VR) regimen in patients with relapsed chronic lymphocytic leukemia in Polish clinical practice
2025-524795-35-00Adult with chronic lymphocytic leukemia/small lymphocytic l…
Uniwersytet Medyczny W Lublinie
Hemic and Lymphatic Diseases
Poland
26/06/2026
Phase IV
A randomised, double-blind, three parallel-group, placebo controlled superiority trial assessing the effect of intravenous versus oral iron supplementation on physical performance, quality of life and cognitive function in iron deficient FRAIL elderly IndiviDuals with cardiovascular disease (FRAIL-ID trial)
2025-521570-34-00Frailty with Iron Deficiency in Elderly Patients with Cardi…
Wroclaw Medical University
Nutritional and Metabolic Diseases
Poland
05/06/2026
Phase IV
A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.
2025-524289-56-00Asthma
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Germany, Romania, Italy, Bulgaria, Poland, Slovakia, Spain, France
18/05/2026
Phase IV
A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
2025-522362-78-00severely active ulcerative colitis (US) and CD (Crohn’s dis…
Eli Lilly & Co.
Immune System Diseases
Spain, Denmark, Germany, Italy, Poland
27/04/2026
Phase IV
A randomized double-blind placebo-controlled study to demonstrate the efficacy of PMBL® sublingual tablets in reducing the incidence of respiratory tract infections in children aged 3-12 years (PIRTIK).
2025-524212-11-00Respiratory Tract Infections
Lallemand Pharma Europe filial af Lallemand Pharma AG Schweiz
Respiratory Tract Diseases
Poland
23/04/2026
Phase IV
Identification of mitochondrial biomarkers reflecting omaveloxolone treatment (in FA patients)
2025-523881-26-00Friedreich's ataxia
Fakultni Nemocnice V Motole
Nervous System Diseases
Czechia, Poland
30/03/2026
Phase IV
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)
2025-522118-21-00Axial Spondyloarthritis, Acute Anterior Uveitis
Care Arthritis Ltd.
Eye Diseases
Spain, Poland, Netherlands, France, Bulgaria, Germany
13/03/2026
Phase IV
Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
2025-521621-33-00Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Ad…
Replimune Group Inc.
Neoplasms
Germany, Greece, France, Poland, Spain
09/02/2026
Phase IV
A multicenter, prospective clinical TRrial evaluating patient’s ability to make an independent and safe decision regarding the USe of the medicinal product Sildenafil Polpharma100 mg indicated in the Treatment of erectile dysfunction. TRUST Trial on Responsible Use and Self-assessed Treatment.
2025-522923-81-00Erectile dysfunction
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Male Urogenital Diseases
Poland
26/01/2026
Phase IV
International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis
2024-519550-36-00Allergic rhinoconjunctivitis
Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l.
Immune System Diseases
Poland, Spain, Italy
19/01/2026
Phase IV
(ASK-PD0-CS002) Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants with Parkinson’s Disease or Multiple System Atrophy
2025-522653-19-00Multiple System Atrophy, Parkinson's Disease
Askbio Inc.
Nervous System Diseases
Poland
22/12/2025
Phase IV
A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease (AEOLUS)
2025-521268-37-00Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Netherlands, Hungary, France, Germany, Austria, Spain, Poland, Sweden, Italy, Denmark
29/09/2025
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-europe/country/poland

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.